SEC Form 4 · accession 0001093557-16-000447
DEXCOM INC · DXCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew K Balo
Officer — EVP, Clinical, Regulatory
Period of report
Mar 8, 2016
Accepted (ET)
Mar 10, 2016 · 8:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001093557
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 8, 2016 | A | 38,000 | $0.001 | A | 145,777 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.
- F2Included in this number are 94,667 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 31,666 of which were granted on March 8, 2015 and shall vest through March 8, 2018, 16,667 of which were granted on March 8, 2014 and shall vest through March 8, 2017, and 8,334 of which were granted on March 11, 2013 and shall vest through March 11, 2016.